

Special Issue

Molecular Research in Substance Abuse: Toxicity, Neurotoxicity and Neuropathological Findings

Message from the Guest Editors

The drugs of abuse, consumed either as a single substance or in combination, include opiates, cannabis, cocaine, amphetamines and methamphetamine as well as new psychoactive substances, which represent a recent and growing matter of concern. Since the prevalent pattern of drug abuse is the polydrug consumption, including the combination of drugs and other substances, e.g. alcohol and nicotine, it is nearly impossible to ascribe neuropathological findings to a single substance. Furthermore, many drugs contain potentially neurotoxic adulterants and diluents. This Special Issue will focus on the biological aspects of drug addiction in a broad sense, including genetics, biochemical, physiological, functional or structural correlates found in the brain, but also in peripheral body tissues or organs. Understanding the biological basis of drug addiction will provide valuable opportunities for its prevention, diagnosis and treatment, since biological variables may serve as both biomarkers and therapeutic targets for the disease. Manuscripts dealing with the biological basis of behavioral addictions (i.e. sex, gambling, exercise, social media) are also welcome.

Guest Editors

Dr. Angelo Montana

Department of Excellence Biomedical Sciences and Public Health,
Marche Polytechnic University, 60121 Ancona, Italy

Dr. Arianna Giorgetti

Department of Medical and Surgical Sciences, Section of Legal
Medicine, University of Bologna, 40126 Bologna, Italy

Deadline for manuscript submissions

closed (30 April 2025)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/184821

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).